Table 1. General data of the... | American Society of Hematology

Table 1.

General data of the participants in the developmental and clinical validation cohorts

	Developmental cohorts		Clinical validation cohorts
	Patients with APS (n = 48)	Controls (n = 64)	Patients with APS (n = 33)	Controls (n = 62)	Thrombosis controls (n = 38)
Age, mean ± SD, y	46 ± 14	67 ± 11∗	47 ± 12	69 ± 11∗	47 ± 13†
Sex, n (% male)	18 (38)	47 (73)∗	9 (27)	51 (82)∗	16 (42)†
Primary APS, n (%)	30 (62)		33 (100)
Secondary APS, n (%)	18 (38)		0 (0)
LA, n (%)	39 (81)		29 (88)		0 (0)
Anti-CL antibodies, n (%)	38 (79)		25 (76)		0 (0)
Anti–β2-GPI antibodies, n (%)	27 (56)		34 (81)		0 (0)
Thrombosis, n (%)	48 (100)	4 (6%)∗	31 (94)	7 (11)∗	38 (100)†
Pregnancy morbidity, n (%)	8 (17)		4 (12)		0 (0)
INR‡ (treatment range²¹^,²⁶^,²⁷)	NA (2.0-3.0)	2.8 ± 0.8 (2.0-3.0)	2.5 ± 0.9 (2.0-3.0)	3.1 ± 1.0 (2.0-3.0)	2.1 ± 0.3 (VKA) 1.1 ± 0.3 (non-VKA) (2.0-3.0)

	Developmental cohorts		Clinical validation cohorts
	Patients with APS (n = 48)	Controls (n = 64)	Patients with APS (n = 33)	Controls (n = 62)	Thrombosis controls (n = 38)
Age, mean ± SD, y	46 ± 14	67 ± 11∗	47 ± 12	69 ± 11∗	47 ± 13†
Sex, n (% male)	18 (38)	47 (73)∗	9 (27)	51 (82)∗	16 (42)†
Primary APS, n (%)	30 (62)		33 (100)
Secondary APS, n (%)	18 (38)		0 (0)
LA, n (%)	39 (81)		29 (88)		0 (0)
Anti-CL antibodies, n (%)	38 (79)		25 (76)		0 (0)
Anti–β2-GPI antibodies, n (%)	27 (56)		34 (81)		0 (0)
Thrombosis, n (%)	48 (100)	4 (6%)∗	31 (94)	7 (11)∗	38 (100)†
Pregnancy morbidity, n (%)	8 (17)		4 (12)		0 (0)
INR‡ (treatment range²¹^,²⁶^,²⁷)	NA (2.0-3.0)	2.8 ± 0.8 (2.0-3.0)	2.5 ± 0.9 (2.0-3.0)	3.1 ± 1.0 (2.0-3.0)	2.1 ± 0.3 (VKA) 1.1 ± 0.3 (non-VKA) (2.0-3.0)

INR, International normalized ratio; NA, not available; SD, standard deviation.

P < .001 compared with patients with APS.

No significant difference compared with APS patients.

INR data were not available for all participants; results for a subset of the cohorts is shown.